Clinical trials: Patients with Advanced Solid Tumors
Advanced Solid Tumor
A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2-positive advanced solid tumors.
- Trial name
- NCT04941339
- Testing
- MRG002
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Shanghai Miracogen Inc.
Breast Cancer, Pancreas Cancer
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.
- Conditions
- Breast Cancer, Pancreas Cancer, Prostate Cancer, Lung Cancer
- Trial name
- NCT03199586
- Testing
- NP-G2-044
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Novita Pharmaceuticals, Inc.
Advanced Solid Tumors
A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 in combination with HX008 in patients with EGFR-positive advanced or metastatic solid tumors.
- Trial name
- NCT05688605
- Testing
- MRG003+HX008
- Where
- 2 sites in China
- Volunteers
- 18 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Non-small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC)
An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors
The purpose of the dose escalation part of this study is to determine the feasibility of using the combination of copanlisib and nivolumab in subjects with advanced solid tumors, and to determine the maximum tolerated dose of…
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatocellular Carcinoma (HCC)
- Trial name
- NCT03735628
- Testing
- Copanlisib, Nivolumab
- Where
- 6 sites in United States, Canada
- Volunteers
- 16 people
- Sponsor
- Bayer
Solid Tumors
INVAC-1 Anti-Cancer hTERT DNA Immunotherapy
INVAC-1 is intended to be used for the treatment of adult patients with advanced solid tumors unresponsive to currently available therapies, or for whom no standard therapy is available.
- Trial name
- NCT02301754
- Testing
- INVAC-1
- Where
- 2 sites in France
- Volunteers
- 26 people
- Sponsor
- Invectys
Advanced Cancer
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer.
- Trial name
- NCT04148937
- Testing
- LY3475070, Pembrolizumab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
Solid Tumors
A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Study BP29541 is a first-in-human, open-label, multi-center, dose-escalation Phase I clinical study of single-agent RO6958688 in participants with locally advanced and/or metastatic carcinoembryonic antigen (CEA) positive solid…
- Trial name
- NCT02324257
- Testing
- RO6958688, Obinutuzumab, Tocilizumab
- Where
- 21 sites in United States, Canada and 5 more
- Volunteers
- 149 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor
YL-13027 in Patients With Advanced Solid Tumors
Part 1 (Phase Ia): This is a dose escalation, 3 + 3 design study, to evaluate the safety and tolerability, and to determine the RP2D of YL-13027 when administered b.i.d. in patients with advanced solid tumors.
- Trial name
- NCT05228600
- Testing
- YL-13027
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
Advanced Solid Tumor
A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors
This study is a multicenter, open label, dose exploration/efficacy extension Phase I clinical trial aimed at evaluating the safety, tolerability, pharmacokinetics and efficacy of SHR-1049 injection in patients with advanced solid…
- Trial name
- NCT07380334
- Testing
- SHR-1049 Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Malignancy, Advanced Solid Tumor
Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of ascending doses of AZD5363 under adaptable dosing schedules in Japanese patients with advanced solid…
- Trial name
- NCT01353781
- Testing
- AZD5363
- Where
- Japan
- Volunteers
- 39 people
- Sponsor
- AstraZeneca
Solid Tumor
Study of BM230 in Patients With Advanced Solid Tumors
This study is a Phase I, multicenter, non-randomized, open-label, first-in-human study of BM230 conducted globally. The study will include two parts: a dose escalation part (Phase Ia) followed by a dose expansion part (Phase Ib).
- Trial name
- NCT06644300
- Testing
- BM230
- Where
- 6 sites in Australia, China
- Volunteers
- 123 people
- Sponsor
- Suzhou Biomissile Pharmaceuticals Co., Ltd.
Non Small Cell Lung Cancer
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.
- Trial name
- TRUST-II (NCT04919811)
- Testing
- Taletrectinib
- Where
- 77 sites in United States, Canada and 7 more
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- Nuvation Bio Inc.
Advanced Solid Tumors, Hepatocellular Carcinoma
A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma
This is an open-label, multicenter, phase 1 dose escalation study of BBI503 monotherapy, or BBI503 in combination with Sorafenib.
- Trial name
- NCT02354898
- Testing
- BBI503, Sorafenib
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Solid Tumor
A Study of CBP-1018 in Patients With Advanced Solid Tumors
This is an open-label, non-randomized, multi-center, phase I study of bi-ligand-drug conjugate CBP-1018 in patients with advanced solid tumors.
- Trial name
- NCT04928612
- Testing
- CBP-1018
- Where
- 2 sites in China
- Volunteers
- 170 people
- Sponsor
- Coherent Biopharma (Suzhou) Co., Ltd.
Advanced Solid Malignant Tumors
Open Label Study of DS-5573a
This is an open-label, sequential dose escalation and expansion study to evaluate the safety, and pharmacokinetics of DS-5573a in Japanese patients with advanced solid malignant tumors.
- Trial name
- NCT02192567
- Testing
- DS-5573a
- Where
- Japan
- Volunteers
- 19 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Non Small Cell Lung Cancer, Solid Tumors, Adult
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation.
- Conditions
- Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer, Lung Adenocarcinoma
- Trial name
- NCT05887492
- Testing
- TNG260, Pembrolizumab
- Where
- 13 sites in United States
- Volunteers
- 126 people
- Sponsor
- Tango Therapeutics, Inc.
Breast Cancer, Solid Tumor
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
This is an open-label, multicenter, Phase I study designed to evaluate the safety, tolerability, and pharmacokinetics of inavolisib administered orally as a single agent in patients with locally advanced or metastatic…
- Trial name
- NCT03006172
- Testing
- Inavolisib, Fulvestrant, Letrozole
- Where
- 12 sites in United States, Canada and 3 more
- Volunteers
- 200 people
- Sponsor
- Genentech, Inc.
Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Liver Cancer
Study of Metatinib Tromethamine Tablet
This is an open-label, multicenter study designed to assess the safety, tolerability, preliminary efficacy and pharmacokinetics of Metatinib Tromethamine tablet in patients with advanced or metastatic gastric cancer, liver…
- Conditions
- Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Liver Cancer, Advanced or Metastatic CRC, Advanced or Metastatic Non Squamous NSCLC
- Trial name
- NCT02650375
- Testing
- Metatinib Tromethamine
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Cancer: Solid Tumors
A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)
This study will find the dose limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended Phase 2 dose (RPTD) of MK4827 when administered in combination with standard doses of carboplatin, or carboplatin/paclitaxel…
- Trial name
- NCT01110603
- Testing
- MK-4827, carboplatin, paclitaxel
- Volunteers
- 12 people
- Sponsor
- Tesaro, Inc.
Advanced Solid Tumors
Study of IMC-1121B in Patients With Advanced Solid Tumors
This trial is testing the investigational drug IMC-1121B administered to Japanese participants with advanced solid tumors who have not responded to standard therapy or for whom no standard therapy is available.
- Trial name
- NCT01005355
- Testing
- IMC-1121B
- Where
- Japan
- Volunteers
- 15 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.